Press Releases

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 28, 2025

Download PDF read more

InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025

Download PDF read more

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

Download PDF read more

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Apr 30, 2025

Download PDF read more

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 20, 2025

Download PDF read more

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Mar 07, 2025

Download PDF read more

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025

Download PDF read more

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 25, 2025

Download PDF read more

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 18, 2025

Download PDF read more

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025

Download PDF read more

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025

Download PDF read more

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025

Download PDF read more

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Jan 15, 2025

Download PDF read more

InflaRx Announces Participation in January Events in San Francisco

Jan 07, 2025

Download PDF read more

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Dec 20, 2024

Download PDF read more

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 15, 2024

Download PDF read more

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 08, 2024

Download PDF read more

InflaRx to Report Third Quarter 2024 Results on November 8 and to Participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 11

Oct 31, 2024

Download PDF read more

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 25, 2024

Download PDF read more

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Sep 03, 2024

Download PDF read more

InflaRx Announces Participation in September Investor Events

Aug 27, 2024

Download PDF read more

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 08, 2024

Download PDF read more

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Aug 01, 2024

Download PDF read more

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

Jul 30, 2024

Download PDF read more

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 24, 2024

Download PDF read more

InflaRx Hosts R&D Event Highlighting the Promise of INF904

Jun 05, 2024

Download PDF read more

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 21, 2024

Download PDF read more

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

May 08, 2024

Download PDF read more

InflaRx to Host Virtual R&D Event on June 5 and Report First Quarter 2024 Results on May 8

Apr 30, 2024

Download PDF read more

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Apr 24, 2024

Download PDF read more

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 21, 2024

Download PDF read more

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Mar 19, 2024

Download PDF read more

InflaRx Appoints Jan Medina as Head of Investor Relations

Feb 22, 2024

Download PDF read more

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 25, 2024

Download PDF read more

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Jan 04, 2024

Download PDF read more

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 06, 2023

Download PDF read more

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 01, 2023

Download PDF read more

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 11, 2023

Download PDF read more

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Aug 30, 2023

Download PDF read more

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Aug 10, 2023

Download PDF read more

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Jun 28, 2023

Download PDF read more

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

Jun 21, 2023

Download PDF read more

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

May 11, 2023

Download PDF read more

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

Apr 18, 2023

Download PDF read more

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

Apr 14, 2023

Download PDF read more

InflaRx Announces Public Offering of Ordinary Shares

Apr 11, 2023

Download PDF read more

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023

Download PDF read more

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

Apr 04, 2023

Download PDF read more

InflaRx Reports Full Year 2022 Financial and Operating Results

Mar 22, 2023

Download PDF read more

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

Jan 05, 2023

Download PDF read more

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

Dec 21, 2022

Download PDF read more

InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904

Nov 09, 2022

Download PDF read more

InflaRx Reports Third Quarter 2022 Financial & Operating Results

Nov 09, 2022

Download PDF read more

InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Sep 29, 2022

Download PDF read more

InflaRx to Present at Upcoming Scientific and Investor Conferences

Sep 09, 2022

Download PDF read more

InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine

Sep 08, 2022

Download PDF read more

InflaRx Reports Second Quarter 2022 Financial & Operating Results

Aug 05, 2022

Download PDF read more

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Jul 26, 2022

Download PDF read more

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

Jul 06, 2022

Download PDF read more

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Jun 29, 2022

Download PDF read more

InflaRx to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022

Download PDF read more

InflaRx Reports Third Quarter 2021 Financial & Operating Results

May 12, 2022

Download PDF read more

InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

May 12, 2022

Download PDF read more

InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Mar 31, 2022

Download PDF read more

InflaRx Reports Full Year 2021 Financial and Operating Results

Mar 24, 2022

Download PDF read more

InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

Mar 17, 2022

Download PDF read more

InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

Mar 08, 2022

Download PDF read more

InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa

Feb 28, 2022

Download PDF read more

InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

Feb 16, 2022

Download PDF read more

InflaRx to Present at Annual SVB Leerink Global Health Conference

Feb 08, 2022

Download PDF read more

InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor Home Investors Press Releases InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

Jan 10, 2022

Download PDF read more

InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Jan 05, 2022

Download PDF read more

InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

Jan 05, 2022

Download PDF read more

InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

Nov 15, 2021

Download PDF read more

InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference

Nov 11, 2021

Download PDF read more

InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference

Nov 03, 2021

Download PDF read more

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

Oct 27, 2021

Download PDF read more

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

Oct 19, 2021

Download PDF read more

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

Oct 12, 2021

Download PDF read more

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 09, 2021

Download PDF read more

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

Sep 08, 2021

Download PDF read more

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Aug 10, 2021

Download PDF read more

InflaRx to Present at the BTIG Virtual Biotechnology Conference

Aug 06, 2021

Download PDF read more

InflaRx Reports Second Quarter 2021 Financial & Operating Results

Aug 05, 2021

Download PDF read more

InflaRx to Present at the Raymond James Human Health Innovation Conference

Jun 17, 2021

Download PDF read more

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

Jun 08, 2021

Download PDF read more

Tony Gibney Joins InflaRx Board of Directors

May 21, 2021

Download PDF read more

InflaRx Reports First Quarter 2021 Financial & Operating Results

May 12, 2021

Download PDF read more

InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study

May 11, 2021

Download PDF read more

InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum

Apr 15, 2021

Download PDF read more

InflaRx Reports Full Year 2020 Financial & Operating Results

Mar 25, 2021

Download PDF read more

InflaRx to Present at Upcoming Investor Conferences

Mar 03, 2021

Download PDF read more

InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants

Mar 01, 2021

Download PDF read more

InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants

Feb 25, 2021

Download PDF read more

InflaRx-Announces-Proposed-Offering-of-Common-Shares-and-One-Year-Warrants

Feb 24, 2021

Download PDF read more

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

Feb 11, 2021

Download PDF read more

InflaRx Provides Update on Vilobelimab (IFX-1) Development

Jan 11, 2021

Download PDF read more

InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference

Jan 07, 2021

Download PDF read more

InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis

Jan 05, 2021

Download PDF read more

InflaRx Reports Q3 2020 Financial & Operating Results

Oct 29, 2020

Download PDF read more

Contact us

Address

Press Releases

Press Releases

See also in Investors: